News & Updates

Noninvasive approach useful for detecting postoperative recurrence in Crohn’s disease

17 Dec 2022

A noninvasive diagnostic approach that combines bowel ultrasound and faecal calprotectin test appears to be reliable for detecting disease recurrence in Crohn’s disease (CD) patients who have undergone ileo-cecal resection, according to a study.

Noninvasive approach useful for detecting postoperative recurrence in Crohn’s disease

17 Dec 2022

Lifestyle modification may lower inflammatory bowel disease burden

16 Dec 2022

Adherence to an overall healthy lifestyle appears to prevent a substantial proportion of inflammatory bowel disease, including Crohn’s disease and ulcerative colitis, as reported in a study.

Lifestyle modification may lower inflammatory bowel disease burden

16 Dec 2022

Biologics prolong remission duration in ulcerative colitis

16 Dec 2022

Among patients with ulcerative colitis (UC), treatment with biologic agents may lead to longer remission durations, a recent study has found. However, biologics appear to have no effect on the risk of resection, particularly in moderate to severe active disease.

Biologics prolong remission duration in ulcerative colitis

16 Dec 2022

Uric acid not linked to major depressive disorder

15 Dec 2022

There appears to be no significant association between serum uric acid (SUA) and major depressive disorder (MDD), suggest the results of a meta-analysis and two-sample bidirectional Mendelian randomization (MR) study.

Uric acid not linked to major depressive disorder

15 Dec 2022

ALXN1840 generates rapid, sustained copper mobilization in Wilson disease

15 Dec 2022 by

In individuals with Wilson disease (WD), a rare disease of copper metabolism, ALXN1840 led to significantly greater copper mobilization compared with standard of care (SoC), findings from a rater-blinded phase III study have shown.

ALXN1840 generates rapid, sustained copper mobilization in Wilson disease

15 Dec 2022

Upadacitinib rapidly effective in ulcerative colitis

15 Dec 2022

Treatment with upadacitinib appears to produce improvements in ulcerative colitis (UC) symptoms as early as day 1, as shown in a recent study.

Upadacitinib rapidly effective in ulcerative colitis

15 Dec 2022

Maralixibat improves pruritus across all PFIC types

14 Dec 2022 by

Treatment with maralixibat significantly reduced the severity of pruritus in children with progressive familial intrahepatic cholestasis (PFIC) in the MARCH-PFIC* study presented at The Liver Meeting 2022.

Maralixibat improves pruritus across all PFIC types

14 Dec 2022

Odevixibat improves pruritus, reduces bile acids in children with ALGS

13 Dec 2022 by

Treatment with odevixibat, a potent, selective IBAT* inhibitor, significantly improved pruritus and reduced serum bile acid levels in children with Alagille syndrome (ALGS), according to the ASSERT** trial presented at The Liver Meeting 2022.

Odevixibat improves pruritus, reduces bile acids in children with ALGS

13 Dec 2022

Durvalumab plus gemcitabine-cisplatin improves survival in advanced BTC

12 Dec 2022 by

First-line treatment with durvalumab plus gemcitabine and cisplatin (GC) leads to improved overall (OS) and progression-free survival (PFS) in advanced biliary tract cancer (BTC) across genomic variants, according to the results of the phase III study TOPAZ-1, presented at the ESMO Asia 2022.

Durvalumab plus gemcitabine-cisplatin improves survival in advanced BTC

12 Dec 2022

Resmetirom safe, effective in improving NASH fibrosis markers

12 Dec 2022 by

Treatment with the selective THR-β* agonist resmetirom for 52 weeks was well-tolerated and effective in reducing markers of NASH** fibrosis in a well-compensated Child-Pugh (CP)-A NASH population, a phase III trial has shown.

Resmetirom safe, effective in improving NASH fibrosis markers

12 Dec 2022

News & Updates

Filter by Specialty:

Specialty:

Noninvasive approach useful for detecting postoperative recurrence in Crohn’s disease

Noninvasive approach useful for detecting postoperative recurrence in Crohn’s disease

Lifestyle modification may lower inflammatory bowel disease burden

Lifestyle modification may lower inflammatory bowel disease burden

Biologics prolong remission duration in ulcerative colitis

Biologics prolong remission duration in ulcerative colitis

Uric acid not linked to major depressive disorder

Uric acid not linked to major depressive disorder

ALXN1840 generates rapid, sustained copper mobilization in Wilson disease

ALXN1840 generates rapid, sustained copper mobilization in Wilson disease

Upadacitinib rapidly effective in ulcerative colitis

Upadacitinib rapidly effective in ulcerative colitis

Maralixibat improves pruritus across all PFIC types

Maralixibat improves pruritus across all PFIC types

Odevixibat improves pruritus, reduces bile acids in children with ALGS

Odevixibat improves pruritus, reduces bile acids in children with ALGS

Durvalumab plus gemcitabine-cisplatin improves survival in advanced BTC

Durvalumab plus gemcitabine-cisplatin improves survival in advanced BTC

Resmetirom safe, effective in improving NASH fibrosis markers

Resmetirom safe, effective in improving NASH fibrosis markers